Raymond James Reiterates Buy Rating on Hinge Health, Inc. (HNGE)
Raymond James maintains a Buy rating on Hinge Health, setting a target price of $80.
Key Points
- Raymond James reiterated its Buy rating on Hinge Health, Inc. (HNGE) with a price target of $80 on June 15, 2026.
- Hinge Health shares are trading near $65.34, with a market cap of $5.06 billion and a forward P/E of 20.04.
- Insiders, including Gabriel M.I. Mecklenburg, were active in June, with both buying and planned selling of shares.
Raymond James has reaffirmed its Buy rating on Hinge Health, Inc. (NYSE:HNGE), setting a price target of $80. Analyst Brian Peterson maintained the rating on June 15, 2026, as the stock trades around $65.34.
Other Institutional Activity in Hinge Health
Insight Holdings Group, LLC holds 9,375,164 shares valued at about $361.5 million, with no change in their position. 11.2 Capital Management, LLC also maintained its holdings at 3,704,524 shares worth approximately $142.8 million. Deer Management Co. LLC acquired 2,633,707 shares, while Bit Capital GmbH reduced its position by 1,006,304 shares to 2,309,797 shares, valued at $89.1 million. RTW Investments, LP expanded its stake significantly by 1,576,500 shares, now holding 1,930,000 shares worth $74.4 million.
Hinge Health, Inc. Stock Snapshot
Shares of Hinge Health, Inc. (NYSE:HNGE) are currently trading around $65.34. The company's market cap stands at approximately $5.06 billion with a forward P/E ratio of 20.04. Hinge Health has a 52-week low of $30.08 and a high of $66.90. The stock's 50-day moving average is $50.53, while the 200-day moving average is $47.62. The company has a current ratio of 1.30 and a quick ratio of 1.04, with a debt-to-equity ratio of 2.24.
Recent Earnings
Hinge Health reported revenue of $646.3 million, with a growth rate of 47.2%. The company, however, is not yet profitable, with a net margin of -78.95% and a return on equity of -136.00%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at Hinge Health, Inc.
In recent insider activity, Gabriel M.I. Mecklenburg sold 83,334 shares at an average price of $60.22 on June 1, 2026, under a planned sale. Another planned sale occurred on June 5, 2026, when Mecklenburg sold 50,000 shares at $65.54. Additionally, Kristina Leslie bought 3,837 shares at $52.12 on June 3, 2026.
Analysts Set New Price Targets
On June 15, 2026, Raymond James maintained its Buy rating with an $80 target. Canaccord Genuity also maintained a Buy rating with a $76 target on the same day. Keybanc set a target of $90 on June 12, 2026, while RBC Capital and Truist Securities maintained Buy ratings with targets of $75 and $85, respectively, on June 11, 2026. Barclays set a $70 target, and Needham maintained a $76 target, both on June 11, 2026.
About Hinge Health, Inc.
Hinge Health, Inc. is a healthcare company based in San Francisco, California. It focuses on developing technology-driven solutions for musculoskeletal (MSK) care. The company offers services that address acute injuries, chronic pain, and post-surgical rehabilitation, primarily targeting self-insured employers. Hinge Health uses AI-powered motion tracking and electrical nerve stimulation technology to deliver personalized care. Founded in 2012, the company is led by CEO Daniel A. Perez and employs around 1,437 people.
Bottom Line
Raymond James's reaffirmation of its Buy rating on Hinge Health, Inc. suggests continued confidence in the company's growth potential. Hinge Health's innovative approach to MSK care and its strong market position are key factors that investors are watching closely. As with all 13F filings, remember that these ratings reflect past analysis and may not represent the current market sentiment.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.